Luteinizing hormone releasing hormone analogue in treatment of hypergonadotrophic amenorrhoea

Authors

  • V. MENON,

    Research Registrar
    1. Department of Clinical Endocrinology, Birmingham and Midland Hospital for Women, Sparkhill, Birmingham B11 4HL, UK
    Search for more papers by this author
  • R. LOGAN EDWARDS,

    Consultant Gynaecologist
    1. Department of Obstetrics and Gynaecology, Birmingham and Midland Hospital for Women, Sparkhill, Birmingham B11 4HL, UK
    Search for more papers by this author
  • S. S. LYNCH,

    Principal Biochemist
    1. Department of Clinical Endocrinology, Birmingham and Midland Hospital for Women, Sparkhill, Birmingham B11 4HL, UK
    Search for more papers by this author
  • W. R. BUTT

    Professor of Endocrinology
    1. Department of Clinical Endocrinology, Birmingham and Midland Hospital for Women, Sparkhill, Birmingham B11 4HL, UK
    Search for more papers by this author

Abstract

Summary. The effect of a luteinizing hormone releasing hormone analogue (HOE 766) was studied in four patients with hypergonadotrophic amenorrhoea (resistant ovary syndrome). After an initial phase of stimulation, there was a uniform and sustained suppression of gonadotrophin concentrations in all the patients during the 20–24 days of treatment, presumably due to down-regulation of the pituitary receptors. One patient ovulated after stopping treatment.

Ancillary